Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OMCL
OMCL logo

OMCL Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
44.130
Open
43.290
VWAP
43.60
Vol
321.09K
Mkt Cap
1.99B
Low
42.860
Amount
14.00M
EV/EBITDA(TTM)
17.04
Total Shares
45.48M
EV
1.91B
EV/OCF(TTM)
12.24
P/S(TTM)
1.64
Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions.
Show More

Events Timeline

(ET)
2026-04-29
08:10:00
Omnicell Appoints Rick Couldry as Chief Pharmacy and Clinical Officer
select
2026-04-28 (ET)
2026-04-28
06:40:00
FY26 Revenue Outlook of $1.215B to $1.255B
select
2026-04-28
06:40:00
Sees Q2 Revenue of $307M-$313M
select
2026-04-28
06:40:00
Omnicell Q1 Revenue of $310M Beats Expectations
select

News

Fool
5.0
04-29Fool
Avory & Company Reduces Omnicell Holdings
  • Share Reduction Transaction: On April 29, 2026, Avory & Company disclosed to the SEC that it sold 156,571 shares of Omnicell for approximately $6.55 million, indicating a diminished confidence in the company's future prospects.
  • Decline in Holding Value: Following the sale, the value of Omnicell shares decreased by $8.01 million, reflecting not only the reduction in shares but also the impact of Omnicell's stock price fluctuations, with the current holding valued at $2.57 million.
  • Portfolio Impact: Omnicell now represents only 3.33% of Avory & Company's reportable assets, while its top holding, VOO, accounts for 22.3%, suggesting a preference for other investments over Omnicell.
  • Performance Analysis: Despite Omnicell reporting $310 million in revenue for Q1 2026, a 15% year-over-year increase, its stock has plummeted 68% since 2021, leading to investor caution regarding its long-term performance.
Fool
9.5
04-29Fool
Omnicell Reports Strong Q1 Earnings, Shares Surge Nearly 21%
  • Significant Revenue Growth: Omnicell's Q1 revenue rose nearly 15% year-over-year to just under $310 million, surpassing analyst expectations of $304 million, indicating strong performance in the healthcare tech sector.
  • Product and Service Gains: Product revenue increased by 20% to nearly $175 million, while service revenue grew by 8% to $135 million, reflecting robust demand for the company's core care solutions and connected device portfolio.
  • Net Income Doubled: The company's non-GAAP net income more than doubled from $12 million to $25 million, with earnings per share at $0.55, significantly exceeding the market's expectation of $0.33, showcasing improved execution.
  • Optimistic Future Guidance: Omnicell expects revenue for 2026 to range from $1.22 billion to $1.26 billion and has raised its non-GAAP earnings per share forecast to between $1.80 and $2.00, demonstrating confidence in future performance.
NASDAQ.COM
9.5
04-29NASDAQ.COM
Omnicell Exceeds Revenue and Profit Expectations in Q1
  • Significant Revenue Growth: Omnicell's Q1 revenue rose nearly 15% year-over-year to just under $310 million, surpassing analyst expectations of $304 million, demonstrating strong performance in the healthcare technology sector.
  • Profitability Improvement: The company's net income more than doubled from $12 million last year to $25 million, with non-GAAP earnings per share reaching $0.55, significantly exceeding the market's forecast of $0.33, reflecting enhanced business execution.
  • Optimistic Guidance: Omnicell expects revenue for 2026 to be between $1.22 billion and $1.26 billion, while raising its non-GAAP earnings per share forecast to $1.80 to $2.00, showcasing management's confidence in future growth.
  • Positive Market Reaction: Following the earnings release, the stock surged nearly 21% in a single day, indicating strong investor enthusiasm for Omnicell's robust performance and a positive outlook for its future development.
seekingalpha
9.5
04-28seekingalpha
Omnicell Q1 2026 Earnings Call Highlights
  • Strong Financial Performance: Omnicell reported total revenue of $310 million in Q1 2026, reflecting a 15% year-over-year growth, demonstrating the company's robust execution in the medical device sector, which drives sustained revenue growth and market share expansion.
  • Product and Service Revenue Growth: Product revenue reached $175 million, up 20% year-over-year, while service revenue was $135 million, increasing by 8%, indicating the company's successful response to product mix and customer demand, enhancing future profitability.
  • Optimistic 2026 Outlook: The company maintains its full-year revenue guidance between $1.215 billion and $1.255 billion, while raising expectations for non-GAAP EBITDA and earnings per share, reflecting management's confidence in future growth and positive market demand.
  • Titan XT Commercialization Progress: The Titan XT hardware is expected to begin shipping in the second half of 2026, alongside a phased rollout of OmniSphere functionality, marking a strategic positioning in new product development and market competition aimed at enhancing long-term revenue potential.
seekingalpha
9.5
04-28seekingalpha
Omnicell Reports Q1 2026 Earnings with Strong Guidance Increase
  • Strong Earnings Beat: Omnicell's Q1 2026 non-GAAP EPS of $0.55 exceeded expectations by $0.22, with revenue of $309.88 million reflecting a 14.9% year-over-year increase, surpassing market forecasts by $5.82 million, indicating robust growth in the healthcare automation sector.
  • Significant EBITDA Growth: The non-GAAP EBITDA for Q1 2026 reached $45 million, a substantial increase from $24 million in Q1 2025, showcasing the company's success in cost management and operational efficiency, which enhances investor confidence.
  • Guidance Upgrade: Following the strong Q1 performance, Omnicell raised its full-year guidance for non-GAAP EBITDA and EPS, projecting EBITDA between $153 million and $168 million, reflecting a positive outlook for future performance.
  • Revenue Projections: For Q2 2026, total revenue is expected to range from $307 million to $313 million, with service revenue projected between $525 million and $545 million, demonstrating the company's strategic focus on product innovation and service expansion.
seekingalpha
9.5
04-27seekingalpha
Omnicell Q1 Earnings Announcement Scheduled
  • Earnings Release Date: Omnicell (OMCL) is set to announce its Q1 earnings on April 28 before market open, with a consensus EPS estimate of $0.33, reflecting a 26.9% year-over-year increase, indicating ongoing improvement in profitability.
  • Revenue Growth Expectations: The revenue estimate for Q1 stands at $304.06 million, representing a 12.8% year-over-year growth, which underscores Omnicell's steady sales increase amid strong market demand, further solidifying its market position.
  • Historical Performance: Over the past two years, Omnicell has beaten EPS estimates 88% of the time and has achieved a 100% success rate in beating revenue estimates, demonstrating the company's reliability and execution in financial forecasting.
  • Revision Trends: In the last three months, EPS estimates have seen six upward revisions and one downward revision, while revenue estimates have experienced seven upward revisions with no downward adjustments, indicating growing analyst confidence in Omnicell's future performance.
Wall Street analysts forecast OMCL stock price to rise
6 Analyst Rating
Wall Street analysts forecast OMCL stock price to rise
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
46.00
Averages
54.20
High
63.00
Current: 0.000
sliders
Low
46.00
Averages
54.20
High
63.00
Craig-Hallum
Buy
upgrade
$53 -> $55
AI Analysis
2026-04-29
Reason
Craig-Hallum
Price Target
$53 -> $55
AI Analysis
2026-04-29
upgrade
Buy
Reason
Craig-Hallum raised the firm's price target on Omnicell to $55 from $53 and keeps a Buy rating on the shares. Following the company's beat and raise quarter, the firm believes there is still room for shares to run and wants investors to focus on how the company is positioning itself for the long term. Given the strong demand for demos, the company has increased their available units three times, which Craig-Hallum thinks will enable more customers to see/feel the benefits of Titan. Further, the firm believes continued innovation around OmniSphere and other services should drive enterprise-wide adoption of the company's solutions in the coming periods.
KeyBanc
Overweight
maintain
$60 -> $70
2026-04-29
Reason
KeyBanc
Price Target
$60 -> $70
2026-04-29
maintain
Overweight
Reason
KeyBanc raised the firm's price target on Omnicell to $70 from $60 and keeps an Overweight rating on the shares. After a solid Q1, the firm continues to recommend Omnicell as a top idea this year, with plenty of runway ahead, driven by strong pipeline demand from newly-launched Titan XT cabinets. The company reiterated its FY26 bookings guide, and KeyBanc continues to view this as likely conservative, especially at bottom end, given management's assumption of traditional market share gains this year despite the unique competitive conversion cycle at play.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OMCL
Unlock Now

Valuation Metrics

The current forward P/E ratio for Omnicell Inc (OMCL.O) is 29.50, compared to its 5-year average forward P/E of 31.30. For a more detailed relative valuation and DCF analysis to assess Omnicell Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
31.30
Current PE
29.50
Overvalued PE
43.01
Undervalued PE
19.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
19.10
Current EV/EBITDA
11.33
Overvalued EV/EBITDA
26.55
Undervalued EV/EBITDA
11.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.54
Current PS
1.50
Overvalued PS
4.09
Undervalued PS
0.98

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what about health tech stocks and robots?
Intellectia · 18 candidates
Market Cap: 50.00M - 50.00BWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ROK logo
ROK
Rockwell Automation Inc
47.26B
SYM logo
SYM
Symbotic Inc
36.98B
TER logo
TER
Teradyne Inc
36.32B
VEEV logo
VEEV
Veeva Systems Inc
36.12B
ZBRA logo
ZBRA
Zebra Technologies Corp
12.31B
DOCS logo
DOCS
Doximity Inc
7.50B

Whales Holding OMCL

C
Cramer Rosenthal McGlynn LLC
Holding
OMCL
+3.93%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Omnicell Inc (OMCL) stock price today?

The current price of OMCL is 43.82 USD — it has increased 1.13

What is Omnicell Inc (OMCL)'s business?

Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions.

What is the price predicton of OMCL Stock?

Wall Street analysts forecast OMCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMCL is54.20 USD with a low forecast of 46.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Omnicell Inc (OMCL)'s revenue for the last quarter?

Omnicell Inc revenue for the last quarter amounts to 309.88M USD, increased 14.91

What is Omnicell Inc (OMCL)'s earnings per share (EPS) for the last quarter?

Omnicell Inc. EPS for the last quarter amounts to 0.25 USD, decreased -266.67

How many employees does Omnicell Inc (OMCL). have?

Omnicell Inc (OMCL) has 3580 emplpoyees as of May 12 2026.

What is Omnicell Inc (OMCL) market cap?

Today OMCL has the market capitalization of 1.99B USD.